Gian Luca Vita

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9187692/publications.pdf

Version: 2024-02-01

71	2,367	172443	223791
papers	citations	29 h-index	46 g-index

74	74	74	3167
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates. Journal of Endocrinological Investigation, 2022, 45, 517-525.	3.3	5
2	Genetic modifiers of upper limb function in Duchenne muscular dystrophy. Journal of Neurology, 2022, 269, 4884-4894.	3.6	2
3	Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen. European Journal of Neurology, 2021, 28, 602-608.	3.3	9
4	A Phase 1/2 Study of Flavocoxid, an Oral NF-ÎºB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences, 2021, 11, 115.	2.3	9
5	Type I SMA â€œnew natural historyâ€• longâ€term data in nusinersenâ€treated patients. Annals of Clinical and Translational Neurology, 2021, 8, 548-557.	3.7	35
6	Have Duchenne Muscular Dystrophy Patients an Increased Cancer Risk?. Journal of Neuromuscular Diseases, 2021, 8, 1063-1067.	2.6	3
7	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. PLoS ONE, 2021, 16, e0253882.	2.5	6
8	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 479-488.	0.6	0
9	Health related quality of life in young, steroid-naÃ¯ve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 1161-1168.	0.6	4
10	Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle and Nerve, 2021, 64, 552-559.	2.2	18
11	Practical approach to respiratory emergencies in neurological diseases. Neurological Sciences, 2020, 41, 497-508.	1.9	33
12	microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors. Cancer Treatment and Research Communications, 2020, 24, 100203.	1.7	2
13	Is it the right time for an infant screening for Duchenne muscular dystrophy?. Neurological Sciences, 2020, 41, 1677-1683.	1.9	9
14	Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp>. Annals of Neurology, 2020, 88, 1109-1117.	5.3	34
15	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Frontiers in Genetics, 2020, 11, 131.	2.3	49
16	Circulating miRNAs expression as potential biomarkers of mild traumatic brain injury. Molecular Biology Reports, 2020, 47, 2941-2949.	2.3	14
17	Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 102.	2.9	11
18	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2020, 7, 786-798.	3.7	36

#	Article	IF	Citations
19	Psychosocial impact of sport activity in neuromuscular disorders. Neurological Sciences, 2020, 41, 2561-2567.	1.9	8
20	Effect of exercise on telomere length and telomere proteins expression in mdx mice. Molecular and Cellular Biochemistry, 2020, 470, 189-197.	3.1	9
21	Respiratory function and therapeutic expectations in DMD: families experience and perspective. Acta Myologica, 2020, 39, 121-129.	1.5	0
22	Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance. Acta Myologica, 2020, 39, 191-199.	1.5	3
23	Longitudinal natural history in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2019, 29, 857-862.	0.6	23
24	Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE, 2019, 14, e0218683.	2.5	47
25	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences, 2019, 40, 661-669.	1.9	32
26	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurological Sciences, 2019, 40, 671-681.	1.9	20
27	Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. Journal of Medical Genetics, 2019, 56, 293-300.	3.2	30
28	6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscular Disorders, 2019, 29, 213-220.	0.6	14
29	Hippo signaling pathway is altered in Duchenne muscular dystrophy. PLoS ONE, 2018, 13, e0205514.	2.5	37
30	Clinical management of Duchenne muscular dystrophy: the state of the art. Neurological Sciences, 2018, 39, 1837-1845.	1.9	31
31	Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS ONE, 2018, 13, e0199223.	2.5	45
32	Emotional burden and coping strategies in amyotrophic lateral sclerosis caregivers: the role of metacognitions. Minerva Psychiatry, 2018, 59, .	0.3	6
33	Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center. Neurological Sciences, 2018, 39, 1961-1964.	1.9	5
34	Sleep disorders in spinal muscular atrophy. Sleep Medicine, 2017, 30, 160-163.	1.6	18
35	Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. Neuromuscular Disorders, 2017, 27, 447-451.	0.6	42
36	Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions. Acta Myologica, 2017, 36, 19-24.	1.5	4

#	Article	IF	Citations
37	Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs. Acta Myologica, 2017, 36, 41-45.	1.5	6
38	Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS ONE, 2016, 11, e0151445.	2.5	32
39	Novel outcome measures for Charcotâ˜Marieâ˜Tooth disease: validation and reliability of the 6â€min walk test and StepWatch^{â„¢} Activity Monitor and identification of the walking features related to higher quality of life. European Journal of Neurology, 2016, 23, 1343-1350.	3.3	26
40	MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet Journal of Rare Diseases, 2016, 11, 91.	2.7	70
41	Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscular Disorders, 2016, 26, 374-377.	0.6	13
42	Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy?. Neuromuscular Disorders, 2016, 26, 261-263.	0.6	3
43	Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report. Osteoporosis International, 2016, 27, 3655-3659.	3.1	18
44	Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 643-649.	0.6	144
45	Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 576-583.	0.6	57
46	Sport activity in Charcotâ€“Marieâ€“Tooth disease: A case study of a Paralympic swimmer. Neuromuscular Disorders, 2016, 26, 614-618.	0.6	14
47	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders, 2016, 26, 126-131.	0.6	142
48	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.6	32
49	Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2016, 11, e0160195.	2.5	43
50	Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice. BioFactors, 2015, 41, 324-329.	5.4	10
51	Burden, professional support, and social network in families of children and young adults with muscular dystrophies. Muscle and Nerve, 2015, 52, 13-21.	2.2	35
52	Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscular Disorders, 2015, 25, 749-753.	0.6	41
53	Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care?. Neuropediatrics, 2015, 46, 033-036.	0.6	9
54	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. PLoS ONE, 2015, 10, e0141240.	2.5	58

#	Article	IF	Citations
55	Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. PLoS ONE, 2014, 9, e108205.	2.5	98
56	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. PLoS ONE, 2014, 9, e83400.	2.5	65
57	Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 201-206.	0.6	83
58	â€œI have got something positive out of this situationâ€¦ psychological benefits of caregiving in relatives of young people with muscular dystrophy. Journal of Neurology, 2014, 261, 188-195.	3.6	37
59	The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys. PLOS Currents, 2014, 6, .	1.4	24
60	Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study. Acta Myologica, 2014, 33, 136-43.	1.5	24
61	Duchenne muscular dystrophy and epilepsy. Neuromuscular Disorders, 2013, 23, 313-315.	0.6	60
62	ANT1 is reduced in sporadic inclusion body myositis. Neurological Sciences, 2013, 34, 217-224.	1.9	9
63	Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. European Journal of Human Genetics, 2013, 21, 630-636.	2.8	39
64	24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2013, 8, e52512.	2.5	99
65	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.1	81
66	Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Skeletal Radiology, 2012, 41, 955-961.	2.0	105
67	Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy. Neurobiology of Aging, 2011, 32, 2190-2197.	3.1	31
68	The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-Î± activation and ameliorates muscle function and morphology in mdx mice. Neuromuscular Disorders, 2011, 21, 579-589.	0.6	31
69	New aspects on patients affected by dysferlin deficient muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 946-953.	1.9	79
70	Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. Neuromuscular Disorders, 2009, 19, 44-48.	0.6	20
71	Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone. Experimental Neurology, 2009, 220, 349-358.	4.1	58